RPH 104

Drug Profile

RPH 104

Alternative Names: RPH-104

Latest Information Update: 23 Feb 2016

Price : $50

At a glance

  • Originator TRPHARM
  • Class Anti-inflammatories
  • Mechanism of Action Interleukin 1 beta inhibitors; Signal transduction pathway inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Inflammation

Most Recent Events

  • 01 Jan 2016 Phase-I clinical trials in Inflammation (In volunteers) in Turkey (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top